Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Inclusion Criteria:

* Histologically or cytologically confirmed renal cell cancer

  * Metastatic disease
  * More than 75% clear cell histology
* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
* No prior refractory disease, defined as clinical or radiologic progression, during or within 3 months after completion of prior interleukin-2 (IL-2)
* Nominally "good" or "intermediate" risk disease, meeting ≥ 4 out of 5 of the following criteria:

  * Hemoglobin \> 10 g/dL (except for patients with hereditary hemoglobinopathy)
  * ECOG performance status 0-1 (required)
  * Calcium normal (corrected)

    * Patients with hypercalcemia due to malignancy allowed provided it has been controlled for \> 1 month
  * Primary tumor treated or resected by complete nephrectomy, partial nephrectomy, radiofrequency ablation, or other local ablation
  * Lactic dehydrogenase \< 1.5 times upper limit of normal (ULN)
* No history of or current brain or CNS metastasis by CT scan or MRI within the past 30 days
* Performance status - ECOG 0-1
* More than 4 months
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 75,000/mm\^3
* No history of bleeding diathesis
* PTT \< 1.5 times ULN
* INR \< 1.5
* Bilirubin ≤ 1.5 times ULN
* AST and ALT ≤ 2.5 times ULN
* No chronic hepatitis B or C
* Creatinine ≤ 2.0 mg/dL
* No proteinuria\* by dipstick urinalysis
* Urine protein ≤ 1,000 mg by 24-hour urine collection
* No symptomatic congestive heart failure
* No uncontrolled hypertension, defined as systolic blood pressure (BP) \> 160 mm Hg and diastolic BP \> 90 mm Hg
* No cardiac arrhythmia
* No peripheral vascular disease ≥ grade 2
* No clinically significant peripheral artery disease
* None of the following arterial thromboembolic events within the past 6 months:

  * Transient ischemic attack
  * Cerebrovascular accident
  * Unstable angina pectoris
  * Myocardial infarction
* Not pregnant
* No nursing during and for 3 months after completion of study treatment
* Negative pregnancy test
* Fertile patients must use effective contraception before, during, and for 3 months after completion of study treatment
* No active infection requiring parenteral antibiotics
* No known HIV positivity
* No history of allergic reaction to antibody drugs or IL-2
* No psychiatric illness or social situation that would preclude study compliance
* No non-healing wound or fracture
* No insulin-dependent diabetes
* No other uncontrolled illness
* No other malignancy requiring active treatment within the past 2 years except nonmelanoma skin cancer
* No prior bevacizumab
* At least 6 months since prior immunotherapy containing IL-2
* At least 2 months since prior investigational antibodies
* More than 4 weeks since prior conventional cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
* No concurrent corticosteroids except replacement corticosteroids for adrenal insufficiency OR inhaled steroids for chronic obstructive pulmonary disease, asthma, or allergic rhinitis
* More than 3 weeks since prior radiotherapy and recovered
* No prior radiotherapy to the only site of measurable disease unless there has been subsequent disease progression
* More than 4 weeks since prior major surgery
* At least 24 hours since prior minor surgical procedure, placement of vascular access device, or fine needle aspiration
* At least 30 days since prior and no other concurrent investigational agents
* More than 10 days since prior anticoagulants

  * Low-dose anticoagulants for maintenance of vascular access device patency allowed
* No concurrent therapeutic warfarin, including warfarin for treatment of deep vein thrombosis or pulmonary embolism
* No other concurrent anticancer therapy